Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.69 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.60 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | LDHA | P00338 | 2/20 | 0.53 |
| ▸ | LDHB | P07195 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11558158 | 1.00 | HCAR3 (0.69) | HCAR3HCAR2NOX1HDAC3HDAC1 | |
| SCHEMBL11562755 | 0.87 | HCAR3 (0.64) | HCAR3HCAR2NOX1HDAC3HDAC1 | |
| SCHEMBL11559613 | 0.85 | HCAR3 (0.61) | HCAR3HCAR2GCK | |
| SCHEMBL31521466 | 0.82 | HCAR3 (0.61) | HCAR3HCAR2GCK | |
| Isopropylamine SCHEMBL16799393 | 0.78 | HCAR3 (0.90) | HCAR3HCAR2 | |
| Isopropylamine SCHEMBL16799391 | 0.78 | HCAR3 (0.90) | HCAR3HCAR2 | |
| SCHEMBL22078580 | 0.77 | HCAR3 (0.54) | HCAR3HCAR2LDHALDHBGCK | |
| Nitrous Acid SCHEMBL27773990 | 0.77 | HCAR3 (0.88) | HCAR3HCAR2 | |
| SCHEMBL23938187 | 0.76 | HDAC4 (0.48) | NOX1HDAC1HDAC6 | |
| SCHEMBL20731184 | 0.76 | MAP4K4 (0.52) | NOX1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890828-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| CN-113226462-A | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | HCAR3 1706/4885HCAR2 929/4885NOX1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.